Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAIGTE)

Drug Name
SurVaxM Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 2 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMAIGTE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Apoptosis inhibitor survivin (BIRC5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS 23722 DMQZI7K Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
CV-9201 DMCPZYT Non-small-cell lung cancer 2C25.Y Phase 1/2 [5]
EZN-3042 DMXFY18 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis inhibitor survivin (BIRC5) TTTPU1G BIRC5_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT04013672) Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71.
5 National Cancer Institute Drug Dictionary (drug id 648549).
6 SPC3042: a proapoptotic survivin inhibitor.Mol Cancer Ther.2008 Sep;7(9):2736-45.